Asgn Inc. Appoints Patricia Obermaier to Board

Asgn Incorporated (NYSE: ASGN) has announced the appointment of Patricia Obermaier to its board of directors, effective immediately. Ms. Obermaier, a seasoned technology professional with over 30 years of industry experience, has been an executive at Microsoft Corporation since July 2019, serving as its Chief Growth Officer and VP of Strategic Initiatives for the company's $12 billion global health life sciences division.

Asgn's CEO, Ted Hanson, expressed his enthusiasm about Ms. Obermaier's appointment, highlighting her strategic vision and operational expertise as valuable assets for the company's growth in the IT consulting business and delivery of innovative solutions to clients across commercial and government sectors.

In addition to Ms. Obermaier's appointment, Asgn also recognized the retirement of board director Mariel Joliet, who has served as a director since December 2016. The retirement of Ms. Joliet, along with the previously announced retirement of fellow director and former audit committee chair Marty Kittrell, brings the total number of Asgn's directors to 10, with three being women.

Asgn's commitment to inclusion in the workplace and board diversity is evident, with more information on this topic available in the company's 2023 ESG report, set to be published shortly and accessible on Asgn's website.

This move comes at a pivotal time in the company's evolution, as Asgn continues to deliver high-value services and solutions to its clients across various sectors. The addition of Ms. Obermaier to the board, along with the recognition of retiring directors, reflects Asgn's strategic focus on leveraging top industry talent to drive its future success. As a result of these announcements, the company's shares have moved -1.6% on the market, and are now trading at a price of $88.0. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.